The GLP-1 scientists, Akiko Iwasaki, Michael J. Fox, Hadiza Galadanci, Vivek Murthy +92 more
Jens Juul Holst, Joel Habener, Svetlana Mojsov, and Dan Drucker PAVING THE WAY FOR WEIGHT-LOSS DRUGS
If [GLP-1 drugs] show benefit for even half of these conditions, then that will be a tremendous win for people struggling with them.' -DAN DRUCKER
Newly powerful weight-loss drugs became the biggest story in health in the past year-and Jens Juul Holst, Joel Habener, Svetlana Mojsov, and Dan Drucker played pivotal roles in making those medications possible. The scientists conducted the early work, beginning in the 1970s, on glucagon-like peptides, or GLPs, that first transformed the treatment of diabetes and now that of obesity.
As with many groundbreaking medical developments, it was a group effort. Holst, at the University of Copenhagen, noticed that after intestinal surgery, patients' levels of insulin soared while their blood-sugar levels dropped; he attributed the changes to several gut-related hormones, including glucagon, which is made in the pancreas. Around the same time, an ocean and a continent away in Boston, Habener and Drucker worked with animals in the lab at Massachusetts General Hospital and identified new types of glucagon hormones that they called GLP-1 and GLP-2. Mojsov, a chemist two floors away, also independently identified the active portion of GLP-1, which is mimicked in the new weight-loss drugs as the key compound in Ozempic and Wegovy (made by Novo Nordisk) and one of two main compounds in Mounjaro and Zepbound (made by Eli Lilly). Mojsov produced large amounts of the peptide and developed antibodies to stick to them. The trio eventually collaborated on critical scientific papers that described the active part of GLP-1 in the guts of rats, and documented that increasing GLP-1 levels corresponded to increasing levels of insulin.
ãã®èšäºã¯ Time ã® May 13, 2024 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ Time ã® May 13, 2024 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³
A timely thriller for a mad, mad world
Aâ70s-style paranoid thriller grounded in the partisan polarization of today
Freshwater reserves
A troubling dip
An exuberant ode to human possibility
VERY RARELY DOES THE RIGHT MOVIE ARRIVE AT precisely the right time, at a moment when compassion is in short supply and the collective human imagination has come to feel shrunken and desiccated.
Broadcasting a crisis for the world to see
ON SEPT. 5, 1972, A 32-YEAR-OLD PRODUCER NAMED Geoffrey S. Mason was working in a control room for ABC Sports in Munich while 12 hostages, including several members of the Israeli Olympic delegation, were being held in a building nearby.
The Power of the Peer
WITH MENTAL-HEALTH CARE IN SHORT SUPPLY, CAN REGULAR PEOPLE FILL THE GAP?
QUEERING THE STORY
Luca Guadagnino directs Daniel Craig in an adaptation of William S. Burroughs' 1985 novella Queer
Shopping under the influence
LTK CO-FOUNDER AMBER VENZ BOX SAW THE FUTURE OF RETAIL. IT TOOK YEARS FOR THE REST OF THE WORLD TO CATCH UP
The Kingmaker
Elon Musk's partnership with the President-elect
Turkey's Erdogan plots his next power grab
RECEP TAYYIP Erdogan is a political survivor.
Why maiden names matter in the age of AI and identity
IN THE DIGITAL AGE, A NAME IS MORE THAN JUST A label. It's tied to our professional history and social media presence.